Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

110.50 -0.36 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Earnings Preview: Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
2 Biotech Growth Stocks I'd Buy Right Now
Both drugmakers seem to have a bright future ahead. 
Via The Motley Fool
Where Sarepta Therapeutics Stands With Analysts
Via Benzinga
What 25 Analyst Ratings Have To Say About Sarepta Therapeutics
Via Benzinga
Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy
Sarepta will sell the Duchenne muscular dystrophy gene therapy under the brand name Elevidys. 
Via Investor's Business Daily
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Biotech Stocks to Sell Before They Damage Your Portfolio
With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point. 
Via InvestorPlace
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
From Sarepta Therapeutics, Inc.
Via Business Wire
24 Analysts Have This to Say About Sarepta Therapeutics
Via Benzinga
NASDAQ:SRPT Shareholder Notice: Investigation over Possible Wrongdoing at Sarepta Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 06/02/2023 -- An investigation was announced concerning possible breaches of fiduciary duties by certain directors at Sarepta Therapeutics, Inc. 
Via SBWire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
While its gene therapy for Duchenne muscular dystrophy has been conditionally approved, it'll take a while to prove its merit. 
Via The Motley Fool
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
Recent events surrounding Sarepta Therapeutics highlights the unpredictability of the biotech industry and its appropriateness solely for high-risk investors. 
Via MarketBeat
Exposures Product Safety
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
Via Benzinga
Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)... 
Via Benzinga
Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy
The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged... 
Via Benzinga
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence
Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a  
Via Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials. 
Via InvestorPlace
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
The stock has now given back all of its 2023 gains as investors' fears mount. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
The FDA told the company that a review of a new therapy will take nearly a month longer. 
Via The Motley Fool
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.